Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Next Previous
Trial Profile

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Malignant thymoma; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CABINET

Most Recent Events

  • 16 Apr 2025 According to an Ipsen media release, the regulatory decision in the European Union for Cabometyx (Cabozantinib) in the treatment of advanced pancreatic (pNETs) and extra-pancreatic (epNETs) neuroendocrine tumors (NETs), based on this study is an anticipated milestone in 2025.
  • 26 Mar 2025 According to an Exelixis media release, based on results from CABINET phase III trial, U.S. Food and Drug Administration (FDA) has approved CABOMETYX (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older.
  • 24 Jan 2025 Results (n=116) , presented in an Exelixis media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top